Clinical Trial

Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This single-arm, open-label study aims to determine the efficacy and safety of low-dose, limited-duration teclistamab as a consolidation scheme in newly diagnosed multiple myeloma (NDMM) patients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-01-02.
Status change: Not Yet Recruiting → Recruiting 2025-03-19
Trial Details
NCT Number NCT06758375
Lead Sponsor Hospital Universitario Dr. Jose E. Gonzalez
Conditions Multiple Myeloma, Newly Diagnosed
Enrollment 10 participants
Start Date 2025-03-03
Primary Completion 2026-09-07 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-03-20